![David T. Molowa](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
David T. Molowa
Directeur/Membre du Conseil chez
University Hospital New Jersey
Profil
Dr. Molowa joined Venrock in 2006 as a Venture Partner.
He has 15 years of experience in life science equity securities research.
Prior to joining Venrock, he was a Managing Director at UBS Securities in New York where he oversaw research in life science equities.
Prior to that, he directed similar research at JP Morgan Securities and at Bear Stearns & Co. Previous to his equity research efforts, he was Senior Researcher Biochemist for Merck & Co. He is currently an advisor to Amgen, Inc. and a member of the board of Directors of Favrille, Inc.
Dr. Molowa is the author and co-author of numerous scientific publications in the field of drug metabolism and gene regulation.
David has a B.S.
in biology from the University of Richmond, a M.B.A. from Rutgers University and a Ph.D.
in Pharmacology/Toxicology, from the Medical College of Virginia.
Postes actifs de David T. Molowa
| Sociétés | Poste | Début |
|---|---|---|
University Hospital New Jersey
 University Hospital New Jersey Medical/Nursing ServicesHealth Services Provides primary health care services for generations of families | Directeur/Membre du Conseil | - |
Anciens postes connus de David T. Molowa
| Sociétés | Poste | Fin |
|---|---|---|
MPM BioEquities Adviser LLC
 MPM BioEquities Adviser LLC Investment ManagersFinance MPM BioEquities Adviser focuses exclusively on global life sciences investments. The firm invests in biotechnology, specialty pharmaceuticals, medical technology and related companies that provide innovative medical products and services to the healthcare industry. They invest across all geographies, stages of development and therapeutic areas. MPM focuses on inflection points in the development of companies, such as the achievement of clinical proof-of-concept data and the achievement of early commercial success, and on reinvigorating commercial platforms with potentially high growth assets. MPM BioVentures I (BB BioVentures, MPM BioVentures Parallel Fund) is a family of funds that was launched in 1997 and is no fully committed with 75% of its investments in biotechnology and 25% in medical devices and other healthcare related fields. The MPM BioVentures I portfolio consists of 26 companies with investments ranging from $5 million to $20 million per company. Within the biotechnology sector, the funds' investments are split between companies focused on therapeutics and enabling technologies. About 80% of the funds' assets are invested in US companies and 20% in European companies. The MPM BioVentures II family of funds closed in the first quarter of 2000. The funds consist of investments in biotechnology, medical devices and other healthcare related fields. The MPM BioVentures II has invested in 35 companies, with investments ranging from $10 million to $50 million. The fund has invested across the entire spectrum of company development, from start-up through mezzanine and PIPES. 85% of the funds' investments are in US companies and 15% are in European and Asian companies. The MPM BioVentures III Fund closed in December of 2002. The fund holds a portfolio of 39 companies, 85% of which are focused on biotechnology and pharmaceutical products and 15% are focused on medical devices and life science tools. The fund's balanced portfolio of early-, mid- and late-stage companies includes investments in public companies through PIPE transactions. The MPM BioVentures IV family of funds was launched in the second quarter of 2006. The funds hold a portfolio of 18 companies with investments ranging from $5 million to $36 million. About 75% of the funds' investments focus on biotechnology and pharmaceutical products and 25% focus on medical device companies. About 25% of the funds' investments have been made outside the US, including investments in Asia and Europe. The MPM BioVentures IV family of funds serves as the lead investor in a majority of its investments and takes an active role as a board member on its portfolio companies' boards of directors. | Directeur en chef des Investissements | 31/07/2009 |
Favrille, Inc.
 Favrille, Inc. Medical SpecialtiesHealth Technology Researches, develops and commercializes targeted immunotherapies for the treatment of cancer and diseases of the immune system | Directeur/Membre du Conseil | 22/04/2009 |
MPM BioImpact LLC
 MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Private Equity Investor | 30/06/2008 |
UBS Securities LLC
 UBS Securities LLC Investment Banks/BrokersFinance Provides brokerage services | Analyst-Equity | 01/01/2006 |
JPMorgan Securities LLC
 JPMorgan Securities LLC Investment Banks/BrokersFinance Provides corporate, investment banking, consumer and commercial banking, asset management, payment & security solutions | Corporate Officer/Principal | 01/01/2004 |
Formation de David T. Molowa
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
97
Relations au 1er degré
12
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 12 |
|---|---|
Bear, Stearns & Co., Inc.
 Bear, Stearns & Co., Inc. Investment Banks/BrokersFinance Provides investment banking, securities trading and brokerage Services | Finance |
Merck & Co., Inc.
 Merck & Co., Inc. Pharmaceuticals: MajorHealth Technology Manufactures human and animal health pharmaceutical products & vaccines | Health Technology |
Venrock Associates
 Venrock Associates Investment ManagersFinance Venrock Associates invests in companies located in the US. The firm focuses on sectors such as intelligent enterprise & AI, security & infrastructure, fintech, healthcare IT, defense & Aerospace, robotics & autonomy and consumer sectors. It participates in early and later stage transactions. | Finance |
UBS Securities LLC
UBS Securities LLC Investment Banks/BrokersFinance Provides brokerage services | Finance |
MPM BioEquities Adviser LLC
MPM BioEquities Adviser LLC Investment ManagersFinance MPM BioEquities Adviser focuses exclusively on global life sciences investments. The firm invests in biotechnology, specialty pharmaceuticals, medical technology and related companies that provide innovative medical products and services to the healthcare industry. They invest across all geographies, stages of development and therapeutic areas. MPM focuses on inflection points in the development of companies, such as the achievement of clinical proof-of-concept data and the achievement of early commercial success, and on reinvigorating commercial platforms with potentially high growth assets. MPM BioVentures I (BB BioVentures, MPM BioVentures Parallel Fund) is a family of funds that was launched in 1997 and is no fully committed with 75% of its investments in biotechnology and 25% in medical devices and other healthcare related fields. The MPM BioVentures I portfolio consists of 26 companies with investments ranging from $5 million to $20 million per company. Within the biotechnology sector, the funds' investments are split between companies focused on therapeutics and enabling technologies. About 80% of the funds' assets are invested in US companies and 20% in European companies. The MPM BioVentures II family of funds closed in the first quarter of 2000. The funds consist of investments in biotechnology, medical devices and other healthcare related fields. The MPM BioVentures II has invested in 35 companies, with investments ranging from $10 million to $50 million. The fund has invested across the entire spectrum of company development, from start-up through mezzanine and PIPES. 85% of the funds' investments are in US companies and 15% are in European and Asian companies. The MPM BioVentures III Fund closed in December of 2002. The fund holds a portfolio of 39 companies, 85% of which are focused on biotechnology and pharmaceutical products and 15% are focused on medical devices and life science tools. The fund's balanced portfolio of early-, mid- and late-stage companies includes investments in public companies through PIPE transactions. The MPM BioVentures IV family of funds was launched in the second quarter of 2006. The funds hold a portfolio of 18 companies with investments ranging from $5 million to $36 million. About 75% of the funds' investments focus on biotechnology and pharmaceutical products and 25% focus on medical device companies. About 25% of the funds' investments have been made outside the US, including investments in Asia and Europe. The MPM BioVentures IV family of funds serves as the lead investor in a majority of its investments and takes an active role as a board member on its portfolio companies' boards of directors. | Finance |
JPMorgan Securities LLC
JPMorgan Securities LLC Investment Banks/BrokersFinance Provides corporate, investment banking, consumer and commercial banking, asset management, payment & security solutions | Finance |
Favrille, Inc.
Favrille, Inc. Medical SpecialtiesHealth Technology Researches, develops and commercializes targeted immunotherapies for the treatment of cancer and diseases of the immune system | Health Technology |
MPM BioImpact LLC
MPM BioImpact LLC Investment ManagersFinance MPM Capital invests in both public and private companies located in the United States. The firm targets companies operating in the fields of biotechnology, healthcare and life science sectors. It participates in early stage capital transactions. | Finance |
Rutgers State University of New Jersey
 Rutgers State University of New Jersey Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University of Richmond
 University of Richmond Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Medical College of Virginia
 Medical College of Virginia Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
University Hospital New Jersey
University Hospital New Jersey Medical/Nursing ServicesHealth Services Provides primary health care services for generations of families | Health Services |
